Milestone Pharmaceuticals Inc. (MIST)
Stock Price:
$3.72 USD
-0.05 (-1.33%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
91.61M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-61.12M |
| Shares Out |
24.63M |
| EPS (ttm) |
-2.81 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$3.72 |
| Previous Close |
$3.77 |
| Change ($) |
-0.05 |
| Change (%) |
-1.33% |
| Day's Open |
3.78 |
| Day's Range |
3.66 - 3.91 |
| Day's Volume |
276,521 |
| 52-Week Range |
1.69 - 25.41 |
More Stats
| Market Cap |
91.61M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.63M |
| Float |
8.21M |
| EPS (basic) |
-2.86 |
| EPS (diluted) |
-2.81 |
| FCF / Share |
-2.24 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.21M |
| Short Ratio |
0.73 |
| Short % of Float |
7.73% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.03 |
| Revenue |
n/a |
| Operating Income |
-63.71M |
| Net Income |
-61.12M |
| Free Cash Flow |
-54.91M |
| Net Cash |
101.46M |
| Net Cash / Share |
4.12 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-43.58% |
| ROE |
-70.67% |
| ROIC |
-436.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
1 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$4.00*
(7.53% upside)
Low
3.00
Current: 3.72
High
6.00
Target: 4.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -57.88 | -23.82 | -8.27 |
| Net Income | -55.23 | -23.19 | -8.09 |
| Shares Outstanding | 15.78 | 0.32 | 0.24 |
| Earnings Per Share | -3.50 | -72.63 | -34.15 |
| Operating Cash Flow | -51.15 | -21.05 | -8.05 |
| Capital Expenditures | -0.41 | -0.01 | -0.04 |
| Free Cash Flow | -51.57 | -21.05 | -8.09 |
| Cash & Equivalents | 120 | 85.98 | 26.91 |
| Total Debt | 0.51 | - | - |
| Net Cash / Debt | 119 | 85.98 | 26.91 |
| Assets | 123 | 88.08 | 27.59 |
| Liabilities | 8.51 | 4.53 | 5.53 |
| Book Value | 115 | -55.21 | -33.12 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Milestone Pharmaceuticals Inc. |
| Country |
Canada |
| Employees |
30 |
| CEO |
Joseph G. Oliveto |
Stock Information
| Ticker Symbol |
MIST |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MIST |
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.